Skip to main content

Table 1 Summary of seroconversion rates and T cell responses amongst patients with cancer and healthy adults

From: Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

  Seroconversion post 1 dose Seroconversion post 2 doses T cell response Modifying factors
Solid organ cancer patients 38–83% [22, 24, 49, 50] 84–98% [20, 21, 24, 25, 49] 71% [24] Use of steroids [24]
Combined chemoimmunotherapy [23, 24]
Haematological malignancies 18–72% [24, 49, 51] 60–85% [20, 21, 24, 25, 27, 49] 50% [24] Anti CD20 treatment [25]
Stem cell transplant [25]
BCMA targeted therapy [27]
Anti CD38 regimens [27]
Disease response [51]
Healthy adults 100% [28, 52] 100% [28, 52] 94% [28] Age [28]
  1. Detectable anti-Spike antibodies
  2. BCMA B cell maturation antigen